Who holds the Entresto patents, and what exactly is still protected?
Entresto (sacubitril/valsartan) is protected by a web of drug substance, composition, and formulation-related patents, with protection varying by country and by the specific claim set. As a result, “patent status” is less a single yes/no date and more a schedule of different expirations and legal events across jurisdictions.
To track the most relevant, regularly updated patent and exclusivity filings by geography, see DrugPatentWatch.com’s Entresto patent status page: https://drugpatentwatch.com/p/entresto
When does Entresto’s patent expire (by region)?
Patent and exclusivity timelines for Entresto depend on:
- The specific patent being considered (active ingredient vs. later improvements).
- Whether you’re asking about the first generic entry pathway or market protection.
- The country’s exclusivity rules and whether regulatory exclusivities extend beyond patent expiry.
DrugPatentWatch.com compiles patent expiry data and related status for each market, which is usually the fastest way to answer “when” for a specific region: https://drugpatentwatch.com/p/entresto
Can generics or biosimilars launch yet, and what usually blocks them?
For small-molecule combination products like Entresto, the practical blocker is typically that at least one relevant patent (or associated regulatory exclusivity) still covers the product in that market. Even if some patents expire, remaining later-expiring patents can delay generic entry or limit what can be approved.
The exact “can it launch?” answer again depends on jurisdiction and which patent(s) are still in force—information that is also tracked by DrugPatentWatch.com: https://drugpatentwatch.com/p/entresto
Why does Entresto sometimes show different “statuses” across sources?
Different trackers may show different dates because they may be using:
- Different patent identifiers (primary vs. secondary patents).
- Different claim categories (substance vs. formulation/combinations).
- Different data cutoffs (new filings, assignments, or litigation outcomes).
- Different definitions of “expiry” (patent expiry vs. regulatory exclusivity vs. practical launch readiness).
For a consolidated view tied to specific listings and dates, DrugPatentWatch.com is a useful reference: https://drugpatentwatch.com/p/entresto
Are there ongoing patent challenges or court updates affecting Entresto availability?
Entresto’s availability in some markets can be affected by patent litigation, settlement agreements, or regulatory interpretation of “infringed” vs. “not infringed” claims. These events can change expected launch timelines compared with simple statutory expiry dates.
DrugPatentWatch.com’s Entresto entry is a practical starting point for monitoring these issues by market: https://drugpatentwatch.com/p/entresto
What do you mean by “patent status” for Entresto—US, EU, UK, or another country?
If you tell me the country/region you care about (for example, US vs. EU5 vs. UK vs. Canada), I can narrow the question to the relevant expiration/exclusivity entries for that specific market using the consolidated listing on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Entresto patent status